• Users Online: 293
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
EDITORIAL
Year : 2020  |  Volume : 4  |  Issue : 4  |  Page : 49-50

Overcoming COVID-19 in children


Department of Pediatrics, E-Da Hospital, School of Medicine for International Students, I-Shou University, Kaohsiung City, Taiwan

Date of Submission02-Jun-2021
Date of Decision05-Jun-2021
Date of Acceptance10-Jun-2021
Date of Web Publication06-Jul-2021

Correspondence Address:
Yu-Tsun Su
Department of Pediatrics, E-Da Hospital, School of Medicine for International Students, I-Shou University, No. 1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung City.
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/prcm.prcm_12_21

Rights and Permissions

How to cite this article:
Su YT. Overcoming COVID-19 in children. Pediatr Respirol Crit Care Med 2020;4:49-50

How to cite this URL:
Su YT. Overcoming COVID-19 in children. Pediatr Respirol Crit Care Med [serial online] 2020 [cited 2021 Dec 3];4:49-50. Available from: https://www.prccm.org/text.asp?2020/4/4/49/320778



Although the coronavirus disease 2019 (COVID-19) pandemic is still ongoing, the overall number of new daily cases has declined worldwide, especially in the countries that have received a large number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. More than 170 million people have been infected globally with more than 3.5 million deaths. In comparison to the high mortality rate in adults, children are usually asymptomatic or have moderate symptoms.[1] In the review article “Children are not little adults,” Professor Goh reviewed the possible mechanisms for this difference between children and adults. Professor Nong performed a comprehensive review of mucoactive agents that have commonly been used in respiratory diseases for decades, according to the different mechanisms of overproduction and clearance of sputum. In addition, critical infants are an especially fragile pediatric population. Professor Chee reported that the clinical outcomes of critical infants could be improved if interhospital transportations were performed by a specialized transport team and a standard neonatal referral workflow. This new strategy was implemented in July 2019 and is still being used during the COVID-19 pandemic.

The presentations of the COVID-19 infection are less severe in children than in adults. Professor Goh[2] reviewed the pathophysiological mechanisms underlying the differences between children and adults and found that they were caused by a lower number of angiotensin-converting enzyme 2, a strong immune response, and a lower inflammatory response in children. In addition, multisystem inflammatory syndrome, which mainly affects children and adolescents but not adults, is also discussed. Good innate antiviral defenses and lower cytokine responses than adults explain the milder COVID-19 infection in children.

Hsu et al.[3] reviewed mucoactive agents, which are widely used to treat respiratory diseases by changing the properties of sputum or decreasing its production. Professor Nong provides an overview of mucoactive agents according to the different pathophysiologies of mucus hypersecretion and clearance.

Infants are an especially fragile pediatric population. From 2013 to 2016, a complication rate of 44.1% in critically ill infants during interhospital transportations was reported on admission in Hong Kong.[4] After July 2019, a standard neonatal referral workflow and specialized neonatal transport team were implemented at the Hong Kong Children’s Hospital. One year after implementation, Chee et al.[5] reported a marked improvement. Compared to the previous cohort, the rate of documented physiological parameters increased, serious complication rate decreased, and the intervention rate during transport (or within 1h after transport) also significantly decreased. This significant improvement emphasizes the importance of establishing standard protocols including a designated and specialized transport team when a critically ill infant requires interhospital transport and that this is especially important during the COVID-19 pandemic.

The SARS-CoV-2 vaccines are helping to overcome the COVID-19 pandemic. I sincerely hope we can see each other in the near future.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Kabra S. Treatment of mild to moderate COVID-19 in children. Pediatr Respirol Crit Care Med 2020;4:25-7.  Back to cited text no. 1
  [Full text]  
2.
Goh A. Children are not little adults. Pediatr Respirol Crit Care Med2020;4:51-3.  Back to cited text no. 2
  [Full text]  
3.
Hsu LS, Huang YF, Chiou YH, Nong BR. An overview of mucoactive agents. Pediatr Respirol Crit Care Med 2020;4:54-7.  Back to cited text no. 3
  [Full text]  
4.
Leung KK, Lee SL, Wong MS, Wong WH, Yung TC. Clinical outcomes of critically ill infants requiring interhospital transport to a paediatric tertiary centre in Hong Kong. Pediatr Respirol Crit Care Med 2019;3:28-35.  Back to cited text no. 4
  [Full text]  
5.
Chee YY, Wong RM, Chan GC. Reduction of complications in interhospital transport of critically ill infants: Impact of a standardized neonatal referral workflow and specialized neonatal transport team at the Hong Kong Children’s Hospital. Pediatr Respirol Crit Care Med 2020;4:58-9.  Back to cited text no. 5
  [Full text]  




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
References

 Article Access Statistics
    Viewed1031    
    Printed22    
    Emailed0    
    PDF Downloaded193    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]